The Anticancer Effect of Metformin Combined with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients with or Without Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

作者
Qiman Zhang,Jin Zheng,Wen Wang,Elyse M. Cornett,Alan D. Kaye,Ivan Urits,Omar Viswanath,Fei‐Long Wei
出处
期刊:Oncology and therapy [Adis, Springer Healthcare]
卷期号:10 (2): 363-375 被引量:7
标识
DOI:10.1007/s40487-022-00209-0
摘要

INTRODUCTION: Despite the growing evidence for the anticancer effect of metformin or its combination with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), the efficacies and side effects of such strategies in non-small cell lung cancer (NSCLC) patients with or without type 2 diabetes mellitus (T2DM) are not well understood. This meta-analysis was performed to determine the efficacy and side effects of metformin combined with EGFR-TKIs (MET-EGFR-TKIs) for the treatment of NSCLC with or without T2DM. METHODS: PubMed and Cochrane Library databases were used to retrieve relevant studies through August 2020 using the keywords "metformin", "EGFR-TKIs" ("gefitinib" or "erlotinib" or "afatinib" or "icotinib" or "dacomitinib") and "lung cancer". The patients in the experimental group received MET-EGFR-TKIs, while those in the control group received only EGFR-TKIs. The outcome analysis reported overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Random-effect models and fixed-effect models were used to estimate the combined hazard ratio (HR) and odds ratio (OR) depending on the data heterogeneity. Three studies (including 1996 patients) were included in the current meta-analysis. RESULTS: There were significant differences in PFS (HR 0.84; 95% confidence interval (CI) 0.75-0.95; P = 0.004) and OS (HR 0.77; 95% CI, 0.50-1.04; P < 0.001) between the MET-EGFR-TKI and EGFR-TKI groups. Although the ORR (OR 1.38; 95% CI 0.66-2.88; P = 0.105) and DCR (OR 2.61, 95% CI 0.68-9.95, P = 0.160) were improved, there was no statistical significance. OS subgroup analysis showed that the combination was more effective in NSCLC with T2DM than in NSCLC without T2DM (HR 0.84; 95% CI 0.74-0.95; P < 0.005). CONCLUSIONS: MET-EGFR-TKIs provided benefits for PFS and OS, and OS subgroup analysis showed that patients with NSCLC with T2DM received greater benefit than NSCLC patients without T2DM. However, further large-scale, well-designed randomized controlled trials (RCTs) are warranted to confirm the findings in the present investigation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
发了十篇Nature完成签到,获得积分10
2秒前
Tuniverse_发布了新的文献求助10
3秒前
4秒前
喂喂喂发布了新的文献求助10
5秒前
田様的应助被微微采纳,获得10
5秒前
pp完成签到,获得积分10
5秒前
hygogogo完成签到,获得积分20
6秒前
顺利安发布了新的文献求助10
6秒前
科研通AI6.3的应助被Lion采纳,获得30
7秒前
7秒前
科研通AI2S的应助被十七采纳,获得10
8秒前
慕青的应助被愤怒的千易采纳,获得10
8秒前
8秒前
学不会完成签到,获得积分10
8秒前
许俊梁发布了新的文献求助10
8秒前
9秒前
10秒前
阿金发布了新的文献求助10
10秒前
可爱的函函的应助被耍酷思菱采纳,获得10
12秒前
顺利安完成签到,获得积分10
12秒前
丰富的诗蕾完成签到,获得积分20
13秒前
523发布了新的文献求助10
13秒前
14秒前
小蘑菇的应助被笑点低的海冬采纳,获得10
14秒前
852的应助被笑点低的海冬采纳,获得10
14秒前
14秒前
14秒前
大模型的应助被笑点低的海冬采纳,获得10
14秒前
归期关注了科研通微信公众号
14秒前
淡然的舞仙完成签到,获得积分10
14秒前
14秒前
15秒前
lxr完成签到,获得积分10
16秒前
CodeCraft的应助被七七采纳,获得10
16秒前
16秒前
ASDF发布了新的文献求助10
16秒前
传奇3的应助被yy采纳,获得10
16秒前
科研通AI6.4的应助被111采纳,获得10
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181892
求助须知:如何正确求助?哪些是违规求助? 9571628
关于积分的说明 21818984
捐赠科研通 7778258
什么是DOI,文献DOI怎么找? 3433556
关于科研通互助平台的介绍 2557720
邀请新用户注册赠送积分活动 2479621